Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Zanaboni

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Clinical and Experimental Immunology|October 1, 1985
Natural killer cells in intravenous drug abusers with lymphadenopathy syndromeG Poli, M Introna, F Zanaboni, et al.
Gynecologic Oncology|October 1, 1996
Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancerG Bolis, I van Zainten-Przybysz, G Scarfone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimenG Bolis, G Scarfone, L Luchini, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2007
Randomised trial of drains versus no drains following radical hysterectomy and pelvic lymph node dissection: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) study in 234 patientsM Franchi, J B Trimbos, F Zanaboni, et al.
Oncology Reports|May 25, 2011
DNA-ploidy and proliferative activity in uterine-tumors - an in-vivo study using bromodeoxyuridine and flow-cytometryG Franchini, A Tusei, L Babilonti, et al.
Cancer|January 1, 1996
Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomyG Bolis, A Villa, P Guarnerio, et al.
Cancer|January 15, 1998
The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocolR Silvestrini, M G Daidone, S Veneroni, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1997
A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancerG Bolis, G Scarfone, F Zanaboni, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2012
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric studyF Zanaboni, B Grijuela, S Giudici, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 20, 2006
Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of MilanF Raspagliesi, S Kusamura, J C Campos Torres, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Clinical and Experimental Immunology|October 1, 1985
Natural killer cells in intravenous drug abusers with lymphadenopathy syndromeG Poli, M Introna, F Zanaboni, et al.
Gynecologic Oncology|October 1, 1996
Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancerG Bolis, I van Zainten-Przybysz, G Scarfone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimenG Bolis, G Scarfone, L Luchini, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2007
Randomised trial of drains versus no drains following radical hysterectomy and pelvic lymph node dissection: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) study in 234 patientsM Franchi, J B Trimbos, F Zanaboni, et al.
Oncology Reports|May 25, 2011
DNA-ploidy and proliferative activity in uterine-tumors - an in-vivo study using bromodeoxyuridine and flow-cytometryG Franchini, A Tusei, L Babilonti, et al.
Cancer|January 1, 1996
Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomyG Bolis, A Villa, P Guarnerio, et al.
Cancer|January 15, 1998
The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocolR Silvestrini, M G Daidone, S Veneroni, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1997
A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancerG Bolis, G Scarfone, F Zanaboni, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2012
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric studyF Zanaboni, B Grijuela, S Giudici, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 20, 2006
Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of MilanF Raspagliesi, S Kusamura, J C Campos Torres, et al.
Pageof 5